FY2025 EPS Estimates for BMY Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has reduced its FY2025 EPS estimate for Bristol Myers Squibb (BMY) from $6.52 to $6.28, while the consensus estimate stands at $6.74.
• The company reported a quarterly EPS of $1.46, surpassing expectations, with revenue increasing to $12.27 billion compared to the previous year's $11.32 billion.
• Bristol Myers Squibb declared a quarterly dividend of $0.62, yielding 5.6%, with the payout ratio at 100% as of the ex-dividend date on October 3rd.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings per share of $6.28 for the year, down from their previous forecast of $6.52. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Cantor Fitzgerald also issued estimates for Bristol Myers Squibb's FY2026 earnings at $6.08 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period last year, the business posted $2.07 EPS. Bristol Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Several other equities analysts also recently weighed in on the stock. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Citigroup dropped their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $57.14.

Bristol Myers Squibb Trading Down 1.5%

Shares of BMY stock opened at $44.01 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The business has a fifty day simple moving average of $46.26 and a 200-day simple moving average of $47.96. Bristol Myers Squibb has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock has a market cap of $89.57 billion, a P/E ratio of 17.74, a P/E/G ratio of 2.26 and a beta of 0.33.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.6%. Bristol Myers Squibb's payout ratio is 100.00%.

Insiders Place Their Bets

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.07% of the company's stock.

Institutional Trading of Bristol Myers Squibb

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Beacon Investment Advisory Services Inc. boosted its holdings in shares of Bristol Myers Squibb by 2.7% during the 1st quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after buying an additional 212 shares in the last quarter. Exchange Capital Management Inc. boosted its stake in Bristol Myers Squibb by 0.4% during the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company's stock worth $2,541,000 after acquiring an additional 220 shares in the last quarter. 1858 Wealth Management LLC boosted its stake in Bristol Myers Squibb by 3.6% during the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $392,000 after acquiring an additional 221 shares in the last quarter. Parsons Capital Management Inc. RI boosted its stake in Bristol Myers Squibb by 0.3% during the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company's stock worth $3,615,000 after acquiring an additional 224 shares in the last quarter. Finally, Richwood Investment Advisors LLC boosted its position in shares of Bristol Myers Squibb by 1.7% during the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company's stock worth $616,000 after purchasing an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.